Evaluating Ainuovirine for treating HIV/AIDS patients
The Efficacy and Safety of Ainuovirine in the Treatment of HIV-infected/AIDS Patients in China
This study is testing if a new HIV medication called Ainuovirine can help adults with HIV-1 lower their viral load and improve their immune health over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Guangzhou 8th People's Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05420246 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the efficacy and safety of Ainuovirine, a third-generation non-nucleoside reverse transcriptase inhibitor, in HIV-1 infected adults. It includes 450 patients who will receive a daily oral dose of Ainuovirine and will be monitored over 12 months for viral suppression rates and CD4+ T cell counts. The study also assesses safety and drug compliance, alongside collecting demographic and medical history data to provide a comprehensive understanding of Ainuovirine's performance in a real-world clinical setting.
Who should consider this trial
Good fit: Ideal candidates are HIV-infected adults aged 18-60 who are prescribed the Ainuovirine regimen.
Not a fit: Patients currently participating in other interventional clinical trials or those who have previously participated in the ACC007 study may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer and more effective treatment option for HIV-infected patients.
How similar studies have performed: While Ainuovirine has shown promise in previous studies, this specific investigation into its efficacy and safety in the Chinese population is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent Exclusion Criteria: 1. Patients who are participating in other interventional clinical trials; 2. Patients who previously participated in the ACC007 study.
Where this trial is running
Guangzhou, Guangdong
- Guangzhou 8th People's Hospital, Guangzhou Medical University. — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Linghua Li, Doctor
- Email: llheliza@qq.com
- Phone: 13725297174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.